Zusammenfassung

• Objekte (1 geändert, 0 hinzugefügt, 0 gelöscht)
  • Wikiderm.EntryClass[0]

Details

Wikiderm.EntryClass[0]

Eintrag

...	...	@@ -59,19 +59,13 @@
59	59	(% class="Bullet" %)-(%%) Pyoderma gangraenosum
60	60
61	61	(% class="Eintrag-2" %)
62		-(% class="Feature" %)TF:(%%) (% class="Bullet" %)-(%%) Infekte
	62	+(% class="Feature" %)TF:(%%) Infekte
63	63
64	64	(% class="Ebene-2" %)
65	65	(% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV
66	66
67		-(% class="Ebene-1" %)
68		-(% class="Bullet" %)-(%%) Dupilumab
69		-
70		-(% class="Ebene-2" %)
71		-(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2023 Nov 27. [[http:~~/~~/doi.org/10.1111/ajd.14190>>url:http://doi.org/10.1111/ajd.14190]]
72		-
73	73	(% class="Eintrag-2" %)
74		-(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) AGEP
	68	+(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) (% class="Abbreviation" %)AGEP(%%)
75	75
76	76	(% class="Ebene-1" %)
77	77	(% class="Bullet" %)-(%%) Dermatitis herpetiformis
...	...	@@ -85,14 +85,11 @@
85	85	(% class="Ebene-1" %)
86	86	(% class="Bullet" %)-(%%) Pemphigus foliaceus
87	87
88		-(% class="Ebene-1" %)
89		-(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa
	82	+(% class="Eintrag-2" %)
90	90
91		-(% class="Ebene-2" %)
92		-(% class="Feature" %)Bsp:(%%) annular pustular psoriasis
93	93
94		-(% class="Ebene-2" %)
95		-(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]]
	85	+(% class="Ebene-1" %)
	86	+(% class="Bullet" %)-(%%) Psoriasis pustulosa
96	96
97	97	(% class="Ebene-1" %)
98	98	(% class="Bullet" %)-(%%) Tinea incognito
...	...	@@ -134,7 +134,7 @@
134	134	(% class="Feature" %)Lit:(%%) J Dermatol 2000; 27: 669-72
135	135
136	136	(% class="Ebene-3" %)
137		-(% class="Feature" %)PT:(%%) CR
	128	+(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
138	138
139	139	(% class="Ebene-3" %)
140	140	(% class="Feature" %)Altn:(%%) Maxacalcitol
...	...	@@ -143,7 +143,7 @@
143	143	(% class="Feature" %)Lit:(%%) Clin Exp Dermatol. 2015 May 19. [[http:~~/~~/doi.org/10.1111/ced.12680>>url:http://doi.org/10.1111/ced.12680]]
144	144
145	145	(% class="Ebene-5" %)
146		-(% class="Feature" %)Lit:(%%) CR
	137	+(% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%)
147	147
148	148	(% class="Ebene-2" %)
149	149	(% class="Bullet" %)-(%%) Dapson Gel
...	...	@@ -158,7 +158,7 @@
158	158	(% class="Bullet" %)-(%%) Dapson
159	159
160	160	(% class="Ebene-3" %)
161		-(% class="Feature" %)Bed:(%%) GS
	152	+(% class="Feature" %)Bed:(%%) (% class="Abbreviation" %)GS(%%)
162	162
163	163	(% class="Ebene-3" %)
164	164	(% class="Feature" %)Dos:(%%) 100-150 mg/Tag
...	...	@@ -197,11 +197,8 @@
197	197	(% class="Bullet" %)-(%%) Apremilast
198	198
199	199	(% class="Ebene-3" %)
200		-(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
	191	+(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
201	201
202		-(% class="Ebene-3" %)
203		-(% class="Bullet" %)-(%%) Australas J Dermatol. 2023 Aug;64(3):e310-e312. [[http:~~/~~/doi.org/10.1111/ajd.14073>>url:http://doi.org/10.1111/ajd.14073]]
204		-
205	205	(% class="Ebene-2" %)
206	206	(% class="Bullet" %)-(%%) Anti-TNF-alpha
207	207
...	...	@@ -209,8 +209,16 @@
209	209	(% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]**
210	210
211	211	(% class="Ebene-4" %)
212		-(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]
	200	+{{pharMacro style="Ebene-4"}}
	201	+(% class="Feature" %)Phar:(%%) Remicade^^®^^
	202	+{{/pharMacro}}
213	213
	204	+(% class="Ebene-4" %)
	205	+(% class="Feature" %)Dos:(%%) 5 mg/kg i.v.
	206	+
	207	+(% class="Ebene-4" %)
	208	+(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4
	209	+
214	214	(% class="Ebene-3" %)
215	215	(% class="Bullet" %)-(%%) Adalimumab
216	216
...	...	@@ -218,7 +218,7 @@
218	218	(% class="Feature" %)Lit:(%%) Ann Dermatol Venereol. 2013 Dec;140(12):797-800 (Frankreich)
219	219
220	220	(% class="Ebene-5" %)
221		-(% class="Feature" %)PT:(%%) CR
	217	+(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
222	222
223	223	(% class="Ebene-2" %)
224	224	(% class="Bullet" %)-(%%) Guselkumab